行情

ADMP

ADMP

Adamis制药
NASDAQ

实时行情|Nasdaq Last Sale

0.3700
-0.0484
-11.57%
盘后: 0.3650 -0.005 -1.35% 16:07 04/02 EDT
开盘
0.4400
昨收
0.4184
最高
0.4400
最低
0.3651
成交量
81.56万
成交额
--
52周最高
2.324
52周最低
0.2700
市值
2,728.09万
市盈率(TTM)
-0.6527
分时
5日
1月
3月
1年
5年

分析师评级

3位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测ADMP价格均价为1.000,最高价位1.000,最低价为1.000。

EPS

ADMP 新闻

更多
  • Adamis Pharmaceuticals Announces Production of Products by its Subsidiary US Compounding to Aid in the COVID-19 Pandemic
  • GlobeNewswire · 1天前
  • Adamis Pharmaceuticals FY19 Sales $22.1M Up From $15.1M YoY, Cash At End Of Year $8.8M
  • Benzinga · 2天前
  • Adamis Pharmaceuticals Announces 2019 Financial Results and Business Update
  • GlobeNewswire · 2天前
  • Adamis Pharma down 14% on equity offering
  • Seeking Alpha - Article · 02/21 14:51

所属板块

制药
+2.46%
制药与医学研究
+2.57%

热门股票

代码
价格
涨跌幅

ADMP 简况

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company's product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company's lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.
展开

微牛提供Adamis Pharmaceuticals Corp(NASDAQ-ADMP)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的ADMP股票新闻,以帮助您做出投资决策。